Login to Your Account



FDA Panel Backs InterMune Drug for Rare Lung Disease

By Donna Young


Wednesday, March 10, 2010
SILVER SPRING, Md. – An FDA advisory panel Tuesday backed approval of InterMune Inc.'s pirfenidone as a treatment for idiopathic pulmonary fibrosis (IPF), a progressive, irreversible, ultimately fatal disease that affects about 5 million people worldwide, including 100,000 Americans. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription